Articles

Patent Docs: District Court decision raises concerns regarding patent protection for diagnostic methods

Kevin Noonan examines the ‘worrisome’ Ariosa Diagnostics v. Sequenom decision and how the Supreme Court’s earlier Mayo v. Prometheus decision influenced it
Written byKevin Noonan
| 3 min read

The Supreme Court’s Mayo v. Prometheus decision in 2012 signaled renewed concern by the court regarding claims to diagnostic methods, including that patents on such methods could impede the ability of doctors to practice medicine. Whether justified or not, the court’s rationale has (as expected) begun to be translated into decisions at the trial court level. In particular, the decision by Judge Susan Illston of the Northern District of California in Ariosa Diagnostics v. Sequenom to grant summary judgment of invalidity against the patentee warrants consideration for its effects, if upheld, on the viability of diagnostic method patents.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of a multicolored protein structure composed of folded ribbon-like strands against a blue and teal background with scattered spherical particles
Learn how advanced analytical methods support the characterization of antibody–C1q interactions and the qualification of analytical binding assays.